New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
The spread of cardiovascular diseases has the nature of an epidemic, which is enhanced by lipid profile disorders, manifested by hypercholesterolemia. Numerous conventional pharmacological tools for lowering cholesterol associated with low density lipoproteins do not make it possible to achieve targ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5271 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250017959739392 |
|---|---|
| author | S. K. Zyryanov O. I. Butranova |
| author_facet | S. K. Zyryanov O. I. Butranova |
| author_sort | S. K. Zyryanov |
| collection | DOAJ |
| description | The spread of cardiovascular diseases has the nature of an epidemic, which is enhanced by lipid profile disorders, manifested by hypercholesterolemia. Numerous conventional pharmacological tools for lowering cholesterol associated with low density lipoproteins do not make it possible to achieve target values in various categories of patients. Inhibition of proprotein convertase subtilisin/ kexin type 9 (PCSK9) is a promising target in the management of patients with atherosclerotic diseases and includes two main tools — monoclonal antibodies (Alirocumab and Evolocumab) and a small interfering RNA drug (Inclisiran). The presented review is devoted to a comparative analysis of the efficacy and safety of drugs from these groups. |
| format | Article |
| id | doaj-art-c8258f4d78b3438ea4f3e1ba0d7df175 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2022-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-c8258f4d78b3438ea4f3e1ba0d7df1752025-08-20T03:57:22Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-12-01271110.15829/1560-4071-2022-52713712New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapyS. K. Zyryanov0O. I. Butranova1Peoples’ Friendship University of Russia; Moscow City Clinical Hospital № 24Peoples’ Friendship University of RussiaThe spread of cardiovascular diseases has the nature of an epidemic, which is enhanced by lipid profile disorders, manifested by hypercholesterolemia. Numerous conventional pharmacological tools for lowering cholesterol associated with low density lipoproteins do not make it possible to achieve target values in various categories of patients. Inhibition of proprotein convertase subtilisin/ kexin type 9 (PCSK9) is a promising target in the management of patients with atherosclerotic diseases and includes two main tools — monoclonal antibodies (Alirocumab and Evolocumab) and a small interfering RNA drug (Inclisiran). The presented review is devoted to a comparative analysis of the efficacy and safety of drugs from these groups.https://russjcardiol.elpub.ru/jour/article/view/5271inclisiranalirocumabevolocumabpcsk9-targeted therapyhypercholesterolemia |
| spellingShingle | S. K. Zyryanov O. I. Butranova New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy Российский кардиологический журнал inclisiran alirocumab evolocumab pcsk9-targeted therapy hypercholesterolemia |
| title | New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy |
| title_full | New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy |
| title_fullStr | New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy |
| title_full_unstemmed | New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy |
| title_short | New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy |
| title_sort | new opportunities for lowering low density lipoprotein cholesterol comparative characteristics of pcsk9 targeted therapy |
| topic | inclisiran alirocumab evolocumab pcsk9-targeted therapy hypercholesterolemia |
| url | https://russjcardiol.elpub.ru/jour/article/view/5271 |
| work_keys_str_mv | AT skzyryanov newopportunitiesforloweringlowdensitylipoproteincholesterolcomparativecharacteristicsofpcsk9targetedtherapy AT oibutranova newopportunitiesforloweringlowdensitylipoproteincholesterolcomparativecharacteristicsofpcsk9targetedtherapy |